View in EDS HTML Full Text PDF Full Text

A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders.

Saved in:
Bibliographic Details
Title: A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders.
Authors: Levin, Frances R., Mariani, John, Brooks, Daniel J., Pavlicova, Martina, Nunes, Edward V., Agosti, Vito, Bisaga, Adam, Sullivan, Maria A., Carpenter, Kenneth M.
Source: Addiction. Jun2013, Vol. 108 Issue 6, p1084-1094. 11p. 1 Diagram, 3 Charts, 2 Graphs.
Subjects: Antidepressants, Mental depression, Psychotherapy methodology, Cannabis (Genus), Confidence intervals, Controlled release preparations, Epidemiology, Fisher exact test, Hamilton Depression Inventory, Health outcome assessment, Research funding, Statistical sampling, Scales (Weighing instruments), Substance abuse, T-test (Statistics), Logistic regression analysis, Venlafaxine, Data analysis, Randomized controlled trials, Treatment effectiveness, Blind experiment, Data analysis software, Therapeutics
Geographic Terms: United States
Abstract: Aim To evaluate whether venlafaxine-extended release ( VEN- XR) is an effective treatment for cannabis dependence with concurrent depressive disorders. Design This was a randomized, 12-week, double-blind, placebo-controlled trial of out-patients ( n = 103) with DSM- IV cannabis dependence and major depressive disorder or dysthymia. Participants received up to 375 mg VEN- XR on a fixed-flexible schedule or placebo. All patients received weekly individual cognitive-behavioral psychotherapy that primarily targeted marijuana use. Settings The trial was conducted at two university research centers in the United States. Participants One hundred and three cannabis-dependent adults participated in the trial. Measurements The primary outcome measures were (i) abstinence from marijuana defined as at least two consecutive urine-confirmed abstinent weeks and (ii) improvement in depressive symptoms based on the Hamilton Depression Rating Scale. Findings The proportion of patients achieving a clinically significant mood improvement (50% decrease in Hamilton Depression score from baseline) was high and did not differ between groups receiving VEN- XR (63%) and placebo (69%) (χ12 = 0.48, P = 0.49). The proportion of patients achieving abstinence was low overall, but was significantly worse on VEN- XR (11.8%) compared to placebo (36.5%) (χ12 = 7.46, P < 0.01; odds ratio = 4.51, 95% confidence interval: 1.53, 13.3). Mood improvement was associated with reduction in marijuana use in the placebo group ( F1,179 = 30.49, P < 0.01), but not the VEN- XR group ( F1,186 = 0.02, P = 0.89). Conclusions For depressed, cannabis-dependent patients, venlafaxine-extended release does not appear to be effective at reducing depression and may lead to an increase in cannabis use. [ABSTRACT FROM AUTHOR]
Copyright of Addiction is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 87517249
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Levin%2C+Frances+R%2E%22&quot;&gt;Levin, Frances R.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Mariani%2C+John%22&quot;&gt;Mariani, John&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Brooks%2C+Daniel+J%2E%22&quot;&gt;Brooks, Daniel J.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Pavlicova%2C+Martina%22&quot;&gt;Pavlicova, Martina&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Nunes%2C+Edward+V%2E%22&quot;&gt;Nunes, Edward V.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Agosti%2C+Vito%22&quot;&gt;Agosti, Vito&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Bisaga%2C+Adam%22&quot;&gt;Bisaga, Adam&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Sullivan%2C+Maria+A%2E%22&quot;&gt;Sullivan, Maria A.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Carpenter%2C+Kenneth+M%2E%22&quot;&gt;Carpenter, Kenneth M.&lt;/searchLink&gt;
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22Addiction%22&quot;&gt;Addiction&lt;/searchLink&gt;. Jun2013, Vol. 108 Issue 6, p1084-1094. 11p. 1 Diagram, 3 Charts, 2 Graphs.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Antidepressants%22&quot;&gt;Antidepressants&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Mental+depression%22&quot;&gt;Mental depression&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Psychotherapy+methodology%22&quot;&gt;Psychotherapy methodology&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Cannabis+%28Genus%29%22&quot;&gt;Cannabis (Genus)&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Confidence+intervals%22&quot;&gt;Confidence intervals&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Controlled+release+preparations%22&quot;&gt;Controlled release preparations&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Epidemiology%22&quot;&gt;Epidemiology&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Fisher+exact+test%22&quot;&gt;Fisher exact test&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Hamilton+Depression+Inventory%22&quot;&gt;Hamilton Depression Inventory&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Health+outcome+assessment%22&quot;&gt;Health outcome assessment&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Research+funding%22&quot;&gt;Research funding&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Statistical+sampling%22&quot;&gt;Statistical sampling&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Scales+%28Weighing+instruments%29%22&quot;&gt;Scales (Weighing instruments)&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Substance+abuse%22&quot;&gt;Substance abuse&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22T-test+%28Statistics%29%22&quot;&gt;T-test (Statistics)&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Logistic+regression+analysis%22&quot;&gt;Logistic regression analysis&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Venlafaxine%22&quot;&gt;Venlafaxine&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Data+analysis%22&quot;&gt;Data analysis&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Randomized+controlled+trials%22&quot;&gt;Randomized controlled trials&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Treatment+effectiveness%22&quot;&gt;Treatment effectiveness&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Blind+experiment%22&quot;&gt;Blind experiment&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Data+analysis+software%22&quot;&gt;Data analysis software&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Therapeutics%22&quot;&gt;Therapeutics&lt;/searchLink&gt;
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22United+States%22&quot;&gt;United States&lt;/searchLink&gt;
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Aim To evaluate whether venlafaxine-extended release ( VEN- XR) is an effective treatment for cannabis dependence with concurrent depressive disorders. Design This was a randomized, 12-week, double-blind, placebo-controlled trial of out-patients ( n = 103) with DSM- IV cannabis dependence and major depressive disorder or dysthymia. Participants received up to 375 mg VEN- XR on a fixed-flexible schedule or placebo. All patients received weekly individual cognitive-behavioral psychotherapy that primarily targeted marijuana use. Settings The trial was conducted at two university research centers in the United States. Participants One hundred and three cannabis-dependent adults participated in the trial. Measurements The primary outcome measures were (i) abstinence from marijuana defined as at least two consecutive urine-confirmed abstinent weeks and (ii) improvement in depressive symptoms based on the Hamilton Depression Rating Scale. Findings The proportion of patients achieving a clinically significant mood improvement (50% decrease in Hamilton Depression score from baseline) was high and did not differ between groups receiving VEN- XR (63%) and placebo (69%) (χ12 = 0.48, P = 0.49). The proportion of patients achieving abstinence was low overall, but was significantly worse on VEN- XR (11.8%) compared to placebo (36.5%) (χ12 = 7.46, P &lt; 0.01; odds ratio = 4.51, 95% confidence interval: 1.53, 13.3). Mood improvement was associated with reduction in marijuana use in the placebo group ( F1,179 = 30.49, P &lt; 0.01), but not the VEN- XR group ( F1,186 = 0.02, P = 0.89). Conclusions For depressed, cannabis-dependent patients, venlafaxine-extended release does not appear to be effective at reducing depression and may lead to an increase in cannabis use. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of Addiction is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder&#39;s express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=87517249
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/add.12108
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 11
        StartPage: 1084
    Subjects:
      – SubjectFull: Antidepressants
        Type: general
      – SubjectFull: Mental depression
        Type: general
      – SubjectFull: Psychotherapy methodology
        Type: general
      – SubjectFull: Cannabis (Genus)
        Type: general
      – SubjectFull: Confidence intervals
        Type: general
      – SubjectFull: Controlled release preparations
        Type: general
      – SubjectFull: Epidemiology
        Type: general
      – SubjectFull: Fisher exact test
        Type: general
      – SubjectFull: Hamilton Depression Inventory
        Type: general
      – SubjectFull: Health outcome assessment
        Type: general
      – SubjectFull: Research funding
        Type: general
      – SubjectFull: Statistical sampling
        Type: general
      – SubjectFull: Scales (Weighing instruments)
        Type: general
      – SubjectFull: Substance abuse
        Type: general
      – SubjectFull: T-test (Statistics)
        Type: general
      – SubjectFull: Logistic regression analysis
        Type: general
      – SubjectFull: Venlafaxine
        Type: general
      – SubjectFull: Data analysis
        Type: general
      – SubjectFull: Randomized controlled trials
        Type: general
      – SubjectFull: Treatment effectiveness
        Type: general
      – SubjectFull: Blind experiment
        Type: general
      – SubjectFull: Data analysis software
        Type: general
      – SubjectFull: Therapeutics
        Type: general
      – SubjectFull: United States
        Type: general
    Titles:
      – TitleFull: A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Levin, Frances R.
      – PersonEntity:
          Name:
            NameFull: Mariani, John
      – PersonEntity:
          Name:
            NameFull: Brooks, Daniel J.
      – PersonEntity:
          Name:
            NameFull: Pavlicova, Martina
      – PersonEntity:
          Name:
            NameFull: Nunes, Edward V.
      – PersonEntity:
          Name:
            NameFull: Agosti, Vito
      – PersonEntity:
          Name:
            NameFull: Bisaga, Adam
      – PersonEntity:
          Name:
            NameFull: Sullivan, Maria A.
      – PersonEntity:
          Name:
            NameFull: Carpenter, Kenneth M.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: Jun2013
              Type: published
              Y: 2013
          Identifiers:
            – Type: issn-print
              Value: 09652140
          Numbering:
            – Type: volume
              Value: 108
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Addiction
              Type: main
ResultId 1